| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 183,103,432 | 191,814,239 | -4.54 | ||
| Gross Profit (Loss) | 43,851,815 | 60,649,901 | -27.7 | ||
| Operational Profit (Loss) | -7,078,355 | 25,414,034 | - | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | -10,321,822 | 23,514,754 | - | ||
| Total Comprehensive Income Attributable to Shareholders of the Issuer | -10,595,855 | 22,671,317 | - | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 46,643,155 | 67,239,010 | -30.63 | ||
| Profit (Loss) per Share | -0.26 | 0.59 | |||
| All figures are in (Actual) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Actual) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | The Company generated revenues of SAR 183 million during the year 2025, representing a decrease of SAR 8.7 million compared to the previous year. This decline is primarily attributable to the reduction in the scope of the industrial clinics contract with SABIC at the end of 2024, prior to the contract’s full termination in September 2025. Despite this impact, the Company successfully offset most of the decline through enhanced sales strategies, securing new service contracts in strategic various locations in the kingdom, in addition to expanding medical services provided to existing clients. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | The Company recorded a net loss of SAR 10.32 million for the year 2025, compared to a net profit of SAR 23.51 million in the previous year. This shift is primarily attributable to the following: • The gross profit decreased by SAR 16.8 million due to the expiration of the industrial clinics operating contract with SABIC, despite the Company’s success in offsetting most of the impact through improved sales performance, securing new contracts in strategic locations, and expanding services provided to existing clients at competitive profit margins. In addition, the Company continued to invest in and expand new business lines such as the first-aid supplies factory, medical transportation services, and the training center which are expected to generate a positive impact in the upcoming periods. • Recognition of expected credit losses amounting to SAR 14.8 million, due to recording a full provision against receivables owed by SABIC following the filing of a legal claim. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | N/A |
| Reclassification of Comparison Items | As per the requirements of IFRS, the Company has reclassified the following: • Reclassification of 2024 marketing expenses amounting to SAR 752,063 from general and administrative expenses to a separate line item under “Selling and Marketing Expenses” in the statement of profit or loss and other comprehensive income. • Reclassification of 2024 employee-related costs for the sales and marketing departments amounting to SAR 123,800 from general and administrative expenses to a separate line item under “Selling and Marketing Expenses” in the statement of profit or loss and other comprehensive income. |
| Additional Information | Earnings per Share: The loss per share for FY 2025 amounted to SAR (0.26), calculated by dividing the Company’s net loss of SAR (10,321,822) by the weighted average number of shares of 40,000,000 shares, in comparison, the profit per share for FY 2024 amounted to SAR 0.59, calculated by dividing the Company’s net profit of SAR 23,514,754 by the same weighted average number of shares of 40,000,000 shares. |
